I. Paul Singh, MD; Constance Okeke, MD, MSCE; and Zarmeena Vendal, MD, convene to discuss the latest updates on drug delivery and procedural pharmaceuticals in glaucoma treatment—specifically regarding the intracameral bimatoprost implant (Durysta, AbbVie) and iDose TR (travoprost intracameral implant) 75 mcg (Glaukos). They each explain the role of these treatments in their practices and how to identify the noncompliant patients who are the best candidates for this intervention. They also review safety data behind these treatments and share pearls for getting started.

Editorially independent content supported with advertising by Glaukos.